Table 3.

Predictors of virological non-suppression among patients living with HIV under dolutegravir (n = 305) *.

	N	Crude			Adjusted
		OR	95% CI	p-Value	OR	95% CI	p-Value
Age
18–24	29	1			1
25–34	87	0.43	0.17–1.09	0.076	0.33	0.12–0.93	0.035
35–49	133	0.88	0.37–2.05	0.762	0.69	0.25–1.85	0.455
50 and +	56	0.70	0.26–1.83	0.461	0.53	0.17–1.61	0.259
Sex
Female	219	1			1
Male	86	0.89	0.50–1.57	0.688	0.94	0.47–1.87	0.854
Education
None/Primary	195	1			1
Secondary/Tertiary	110	0.93	0.55–1.58	0.802	1.29	0.67–2.48	0.446
Marital status
Living alone	180	1			1
In Union	125	1.22	0.74–2.04	0.435	1.28	0.68–2.42	0.447
Ethnic group
Nilotic	157	1			1
Bantu	72	1.59	0.85–2.99	0.147	180	0.79–3.34	0.122
Semi-Bantu	58	1.50	0.76–2.96	0.243	1.51	0.67–2.93	0.284
Sudanese	18	4.52	1.66–12.34	0.003	4.19	1.43–12.68	0.012
Residence
Rural	17	1			1
Urban	288	0.56	0.16–1.99	0.368	0.62	0.14–2.76	0.527
Creatinine
Normal	233	1			1
Abnormal	72	2.43	1.39–4.25	0.002	2.32	1.22–4.43	0.010
Stage
I and II	159	1			1
III and IV	146	1.74	1.04–2.89	0.034	1.86	1.01–3.43	0.047
Viral load at baseline
<1000 copies/mL	224	1			1
≥1000 copies/mL	81	2.39	1.39–4.12	0.002	3.41	1.64–7.08	0.001
Tobacco consumption
No	239	1			1
Yes	66	0.82	0.43–1.54	0.541	0.79	0.35–1.78	0.565
Status of treatment at baseline
Under ART before inclusion	220	1			1
Self-reported naïve patients with baseline VL < 50 copies/mL	52	1.24	0.521	0.64–2.40	1.44	0.66–3.12	0.361
Self-reported naïve patients with baseline VL ≥ 50 copies/mL	33	1.05	0.912	0.46–2.38	0.32	0.11–0.92	0.034
Exposition time under DTG-based regimen in months
6 to 7	98	1			1
8 to 9	49	0.46	0.18–1.15	0.099	0.71	0.26–1.96	0.510
10 to 12	158	1.28	0.73–2.24	0.384	1.22	0.64–2.33	0.554

*: Those who had viral load results at 6–12 months.